[Lipoprotein-associated phospholipase A2: importance and perspectives].
Type VII phospholipase A2 associated to low density lipoproteins (LDL), also known as platelet-activating factor acetylhydrolase, has been recently indicated as a new non traditional and independent risk factor of coronary disease. After the classification of phospholipase A2 family enzymes, a review is made of the recent physiologic and biochemical knowledges on A2 type VII phospholipase LDL lipoproteins-associated and the role developed in lipoproteins metabolism and atherogenesis. Finally, future therapeutic implications and perspectives depending on these knowledges are pointed out especially by using molecules inhibiting the activity of the enzyme in atherosclerosis therapy. The evaluation of circulating activity of the enzyme may be useful in the prevention and recognition of acute coronary syndromes.
Camici
M
M
Cattedra di Semeiotica Medica, Dipartimento di Medicina Interna, Università degli Studi di Pisa, Pisa. mcamici@tiscalinet.it
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors / Q000502:physiology*; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D010741:Phospholipases A / Q000145:classification / Q000502:physiology; D054467:Phospholipases A2; D012307:Risk Factors
D004791:Enzyme Inhibitors; D008074:Lipoproteins; D010741:Phospholipases A; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase